- Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submission
- Added expert industry leaders to Supervisory Board, further strengthening support for the Company's long-term growth strategy
- NBTXR3 program update from pancreatic cancer study and lung cancer study with MD Anderson expected 4Q 2024 and 1H 2025, respectively
- Update on expansion of product portfolio to include disruptive nanotherapeutic platform Curadigm expected 4Q 2024
- €53.2 million in cash and cash equivalents as of September 30, 2024 with cash runway into 4Q 2025
Nanobiotix Q3 Update Highlights Strategic Moves: Phase 3 Head And Neck Cancer Trial Transferred To Janssen, Curadigm Platform Expansion; €53.2M Cash Reserves
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha